Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300864543> ?p ?o ?g. }
- W4300864543 abstract "Androgen deprivation therapies (ADTs) are important treatments which inhibit androgen-induced prostate cancer (PCa) progression by either preventing androgen biosynthesis (e.g. abiraterone) or by antagonizing androgen receptor (AR) function (e.g. bicalutamide, enzalutamide, darolutamide). A major limitation of current ADTs is they often remain effective for limited durations after which patients commonly progress to a lethal and incurable form of PCa, called castration-resistant prostate cancer (CRPC) where the AR continues to orchestrate pro-oncogenic signalling. Indeed, the increasing numbers of ADT-related treatment-emergent neuroendocrine-like prostate cancers (NePC), which lack AR and are thus insensitive to ADT, represents a major therapeutic challenge. There is therefore an urgent need to better understand the mechanisms of AR action in hormone dependent disease and the progression to CRPC, to enable the development of new approaches to prevent, reverse or delay ADT-resistance. Interestingly the AR regulates distinct transcriptional networks in hormone dependent and CRPC, and this appears to be related to the aberrant function of key AR-epigenetic coregulator enzymes including the lysine demethylase 1 (LSD1/KDM1A). In this review we summarize the current best status of anti-androgen clinical trials, the potential for novel combination therapies and we explore recent advances in the development of novel epigenetic targeted therapies that may be relevant to prevent or reverse disease progression in patients with advanced CRPC." @default.
- W4300864543 created "2022-10-04" @default.
- W4300864543 creator A5001954746 @default.
- W4300864543 creator A5007372658 @default.
- W4300864543 creator A5008318894 @default.
- W4300864543 creator A5009158621 @default.
- W4300864543 creator A5012126052 @default.
- W4300864543 creator A5012690658 @default.
- W4300864543 creator A5013179907 @default.
- W4300864543 creator A5013480180 @default.
- W4300864543 creator A5016697912 @default.
- W4300864543 creator A5028298545 @default.
- W4300864543 creator A5037093226 @default.
- W4300864543 creator A5037239931 @default.
- W4300864543 creator A5043200316 @default.
- W4300864543 creator A5049444258 @default.
- W4300864543 creator A5049667228 @default.
- W4300864543 creator A5055444971 @default.
- W4300864543 creator A5058816521 @default.
- W4300864543 creator A5059544511 @default.
- W4300864543 creator A5059654230 @default.
- W4300864543 creator A5059960789 @default.
- W4300864543 creator A5062143628 @default.
- W4300864543 creator A5076161590 @default.
- W4300864543 creator A5077695396 @default.
- W4300864543 creator A5084771213 @default.
- W4300864543 creator A5087694769 @default.
- W4300864543 creator A5091320190 @default.
- W4300864543 creator A5091615715 @default.
- W4300864543 date "2022-10-03" @default.
- W4300864543 modified "2023-10-06" @default.
- W4300864543 title "Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer" @default.
- W4300864543 cites W1495912963 @default.
- W4300864543 cites W1501286679 @default.
- W4300864543 cites W1508200717 @default.
- W4300864543 cites W1590098473 @default.
- W4300864543 cites W1603797292 @default.
- W4300864543 cites W1804037743 @default.
- W4300864543 cites W1976343579 @default.
- W4300864543 cites W1976491226 @default.
- W4300864543 cites W1993808852 @default.
- W4300864543 cites W1994047807 @default.
- W4300864543 cites W1996127793 @default.
- W4300864543 cites W1998691242 @default.
- W4300864543 cites W1999864225 @default.
- W4300864543 cites W2002012961 @default.
- W4300864543 cites W2005060568 @default.
- W4300864543 cites W2008549629 @default.
- W4300864543 cites W2009109655 @default.
- W4300864543 cites W2019288266 @default.
- W4300864543 cites W2028539169 @default.
- W4300864543 cites W2032588123 @default.
- W4300864543 cites W2042095971 @default.
- W4300864543 cites W2049634718 @default.
- W4300864543 cites W2050713927 @default.
- W4300864543 cites W2051410494 @default.
- W4300864543 cites W2054527237 @default.
- W4300864543 cites W2054621094 @default.
- W4300864543 cites W2071003307 @default.
- W4300864543 cites W2071790247 @default.
- W4300864543 cites W2077503648 @default.
- W4300864543 cites W2083981959 @default.
- W4300864543 cites W2088132910 @default.
- W4300864543 cites W2091098941 @default.
- W4300864543 cites W2094221767 @default.
- W4300864543 cites W2098737737 @default.
- W4300864543 cites W2102333999 @default.
- W4300864543 cites W2103959341 @default.
- W4300864543 cites W2112178933 @default.
- W4300864543 cites W2116582477 @default.
- W4300864543 cites W2119504728 @default.
- W4300864543 cites W2121863482 @default.
- W4300864543 cites W2126253217 @default.
- W4300864543 cites W2130211801 @default.
- W4300864543 cites W2134080318 @default.
- W4300864543 cites W2137279230 @default.
- W4300864543 cites W2137467802 @default.
- W4300864543 cites W2142855214 @default.
- W4300864543 cites W2148416479 @default.
- W4300864543 cites W2150048477 @default.
- W4300864543 cites W2156215080 @default.
- W4300864543 cites W2161112598 @default.
- W4300864543 cites W2163470211 @default.
- W4300864543 cites W2164472870 @default.
- W4300864543 cites W2179708332 @default.
- W4300864543 cites W2235405584 @default.
- W4300864543 cites W2261870911 @default.
- W4300864543 cites W2262087934 @default.
- W4300864543 cites W2312844872 @default.
- W4300864543 cites W2397587334 @default.
- W4300864543 cites W2462985846 @default.
- W4300864543 cites W2514356379 @default.
- W4300864543 cites W2540537925 @default.
- W4300864543 cites W2572174216 @default.
- W4300864543 cites W2586987557 @default.
- W4300864543 cites W2590325921 @default.
- W4300864543 cites W2597062310 @default.
- W4300864543 cites W2599911223 @default.
- W4300864543 cites W2604040637 @default.
- W4300864543 cites W2618533596 @default.